Wednesday 16 September 2026
Night EditionRSS

ZOTPAPER

News without the noise

ZOTPAPER
World

DRC launches Ebola vaccination for healthcare workers amid Bundibugyo strain outbreak

Trials for a dedicated vaccine against the less common strain continue as authorities seek to contain the spread

edit
By LineZotpaper
Published
Read Time3 min
The Democratic Republic of the Congo (DRC) has begun vaccinating frontline healthcare workers against the Bundibugyo strain of Ebola, with trials for a vaccine specifically targeting this variant still ongoing, according to reports from Al Jazeera. The move comes as the country grapples with an outbreak of the hemorrhagic fever, which has historically been less common than the Zaire strain but poses a significant threat to health workers and communities.

The vaccination campaign targets healthcare workers who are at the highest risk of exposure while treating patients. The Bundibugyo strain, first identified in Uganda in 2007, has caused sporadic outbreaks in the region, including a 2012 outbreak in DRC. Unlike the more prevalent Zaire strain, for which a licensed vaccine (Ervebo) exists, there is no approved vaccine for the Bundibugyo strain. The current trials aim to fill that gap, though they are still in the experimental phase.

DRC authorities are racing to contain the outbreak, which has already claimed lives in affected areas. The country has extensive experience with Ebola, having faced multiple outbreaks over the past decade, including the devastating 2018-2020 epidemic in North Kivu and Ituri that killed over 2,200 people. That outbreak was primarily the Zaire strain, and the use of Ervebo was a key tool in controlling it. However, the emergence of the Bundibugyo strain presents new challenges, as existing vaccines may not provide cross-protection.

Healthcare workers are often the first to fall ill during Ebola outbreaks, making their protection a priority. The DRC Ministry of Health, with support from the World Health Organization (WHO) and other partners, is rolling out the experimental vaccine under a compassionate use protocol. The vaccine candidate is based on a similar viral vector technology used in the Zaire strain vaccine, but has been adapted to target the Bundibugyo glycoprotein.

Local and international health officials are closely monitoring the trial's progress. While the vaccine's efficacy has not yet been established in controlled studies, early data from animal models and small human trials have been promising. The decision to vaccinate healthcare workers reflects a risk-benefit assessment that favors potential protection over waiting for full regulatory approval.

Critics have raised concerns about the logistics of deploying an experimental vaccine in a region with limited healthcare infrastructure, as well as the need for informed consent and long-term follow-up. However, supporters argue that the urgent threat of Ebola justifies the approach, especially given the high mortality rate of the disease, which can exceed 50% for the Bundibugyo strain.

As the outbreak unfolds, the DRC government is also implementing standard containment measures, including contact tracing, isolation of suspected cases, and community engagement. The vaccination campaign is a critical component of the response, aiming to reduce the risk of nosocomial transmission and protect the health workforce that is essential for managing the outbreak.

§

Analysis

Why This Matters

  • Protecting healthcare workers: They are the backbone of the outbreak response, and vaccinating them reduces the risk of the health system being overwhelmed by staff infections.
  • Broader significance: Successful trials could lead to a licensed vaccine for the Bundibugyo strain, strengthening global preparedness for Ebola outbreaks.
  • What happens next: If the experimental vaccine proves safe and effective, it could be deployed more widely in the affected communities, potentially curtailing the outbreak.

Background

The Bundibugyo strain of Ebola virus was first identified in 2007 during an outbreak in Uganda. It has since caused smaller outbreaks in Uganda and the DRC, with mortality rates ranging from 25% to 50%. Unlike the Zaire strain, which has been the subject of extensive vaccine research since the 2014-2016 West Africa epidemic, the Bundibugyo strain has received less attention. The DRC has experienced 14 Ebola outbreaks since 1976, making it one of the most affected countries. The current outbreak is the first known to be caused by the Bundibugyo strain since 2012.

Key Perspectives

Healthcare workers in affected areas: They face immediate risk and need protection. Many are eager to receive the experimental vaccine, despite its unproven status, because the alternative – infection – is often fatal. DRC Ministry of Health and WHO: Their priority is to contain the outbreak quickly. They argue that the experimental vaccine is the best available tool, given the lack of alternatives, and that the risk of adverse effects is outweighed by the benefits. Critics and bioethicists: Some question the ethics of deploying an experimental vaccine outside of a formal clinical trial, especially in a context where informed consent may be difficult to obtain. Others worry about the logistical challenges of maintaining a cold chain and monitoring long-term side effects.

What to Watch

  • Preliminary safety and efficacy data from the ongoing vaccination campaign, which could be released in the coming weeks.
  • The number of new cases among healthcare workers – a decline would suggest the vaccine is having an impact.
  • Geographic spread of the outbreak to other provinces or neighboring countries, which would escalate the response.

Sources

newspaper

Zotpaper

Articles published under the Zotpaper byline are synthesized from multiple source publications by our AI editor and reviewed by our editorial process. Each story combines reporting from credible outlets to give readers a balanced, comprehensive view.

Editorial ProcessSubscribe